Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 16.1% on 9/17/25. The shares closed at $11.33. Moreover, trading volume in this advance was exceptionally high at 370% of normal. Relative to the market the stock has been weak over the last nine months and has declined -2.4% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Avalo Therapeutics has a good Appreciation Score of 76 but a poor Power Rating of 28, with the Neutral Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment